Press Releases

FOR IMMEDIATE RELEASE [Covington, KY--- April 18, 2023] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that the Company will be represented at two upcoming prestigious scientific conferences: American Association for Cancer Research Annual Meeting (AACR) April 14-19, 2023 Orlando, Florida Bexion [...]

FOR IMMEDIATE RELEASE [Covington, KY--- April 11, 2023] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that Bexion Pharmaceuticals will be presenting at the Needham Healthcare Conference. The conference will be held virtually from April 17-20, 2023. Scott Shively, Bexion’s CEO and President, [...]

Study achieved planned maximum dose of BXQ-350 with strong safety profile FOR IMMEDIATE RELEASE Covington, KY, February 23, 2022 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today results from their clinical trial entitled, “An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent [...]

Study Aims to Assess Safety and Efficacy of BXQ-350 in Combination with Standard of Care for mCRC FOR IMMEDIATE RELEASE Covington, KY, January 10, 2022 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today that the first adult patient has been dosed in the Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy [...]

Study Aims to Assess Potential for BXQ-350 to Reduce the Intensity and/or Duration of Chemotherapy-Induced Peripheral Neuropathy (CIPN), a Prevalent Limitation of Existing Chemotherapies FOR IMMEDIATE RELEASE Covington, KY, October 18, 2022 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today that the first adult patient has been dosed in the Pilot Proof of [...]

FOR IMMEDIATE RELEASE [Covington, KY--- 14 September 2022] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that an abstract submitted for an in-person session at the EANO annual meeting to be held in Vienna, Austria from September 15-18, 2022 has been chosen for [...]